Javascript must be enabled to continue!
Abstract 2518: Development of a non-hydrolysable phosphotyrosine mimetic peptide based on a high affinity SHP2 substrate
View through CrossRef
Abstract
The Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) is a transducer of growth factor, cytokine, integrin, and hormone signaling pathways that regulate processes such as cell proliferation, differentiation, adhesion, migration, and apoptosis and plays a pivotal role in growth factor and cytokine signaling. Gain-of-function SHP2 mutations are associated with several types of leukemias, and solid tumors. This makes SHP2 an attractive target for developing new anticancer therapy. Several small molecules have been developed for inhibition of this important phosphatase, which serve as chemical tools to probe the role of SHP2 in disease and lead compounds for optimization. Nevertheless improvements are required to improve these lead compounds with better potency, selectivity and cell permeability. To gain structural insights for development of potent and selective Shp2 inhibitors, we synthesized a non-hydrolysable phosphotyrosine peptide mimetic, based on reported Shp2 substrate peptide sequences. The non-hydrolyzable phosphopeptide, containing the phosphotyrosyl surrogate difluoromethylphosphonate, was prepared by solid phase peptide synthesis methods from the known building block N-FMOCF2Pmp. We will present the synthesis of the peptide, analysis of Shp2 phosphatase inhibition, and binding of the phosphopeptide mimic to SHP2 by micro isothermal calorimetry. We will present a model for the binding mode of the peptide and its implications for the design of selective Shp2 inhibitors.
Citation Format: Harshani R. Lawrence, Yiyu Ge, Andreas Becker, Yuan Ren, Yunting Luo, Jie Wu and Nicholas J. Lawrence. Development of a non-hydrolysable phosphotyrosine mimetic peptide based on a high affinity SHP2 substrate. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2518. doi:10.1158/1538-7445.AM2014-2518
American Association for Cancer Research (AACR)
Title: Abstract 2518: Development of a non-hydrolysable phosphotyrosine mimetic peptide based on a high affinity SHP2 substrate
Description:
Abstract
The Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) is a transducer of growth factor, cytokine, integrin, and hormone signaling pathways that regulate processes such as cell proliferation, differentiation, adhesion, migration, and apoptosis and plays a pivotal role in growth factor and cytokine signaling.
Gain-of-function SHP2 mutations are associated with several types of leukemias, and solid tumors.
This makes SHP2 an attractive target for developing new anticancer therapy.
Several small molecules have been developed for inhibition of this important phosphatase, which serve as chemical tools to probe the role of SHP2 in disease and lead compounds for optimization.
Nevertheless improvements are required to improve these lead compounds with better potency, selectivity and cell permeability.
To gain structural insights for development of potent and selective Shp2 inhibitors, we synthesized a non-hydrolysable phosphotyrosine peptide mimetic, based on reported Shp2 substrate peptide sequences.
The non-hydrolyzable phosphopeptide, containing the phosphotyrosyl surrogate difluoromethylphosphonate, was prepared by solid phase peptide synthesis methods from the known building block N-FMOCF2Pmp.
We will present the synthesis of the peptide, analysis of Shp2 phosphatase inhibition, and binding of the phosphopeptide mimic to SHP2 by micro isothermal calorimetry.
We will present a model for the binding mode of the peptide and its implications for the design of selective Shp2 inhibitors.
Citation Format: Harshani R.
Lawrence, Yiyu Ge, Andreas Becker, Yuan Ren, Yunting Luo, Jie Wu and Nicholas J.
Lawrence.
Development of a non-hydrolysable phosphotyrosine mimetic peptide based on a high affinity SHP2 substrate.
[abstract].
In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA.
Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2518.
doi:10.
1158/1538-7445.
AM2014-2518.
Related Results
Tau associates with protein tyrosine phosphatase SHP2
Tau associates with protein tyrosine phosphatase SHP2
<p>The microtubule-associated protein tau normally functions to bind to and stabilize microtubules. However, evidence now indicates that tau may also play a critical role in ...
Macrophage SHP2 Deficiency Alleviates Diabetic Nephropathy via Suppression of MAPK/NF-κB-Dependent Inflammation
Macrophage SHP2 Deficiency Alleviates Diabetic Nephropathy via Suppression of MAPK/NF-κB-Dependent Inflammation
Increasing evidence implicates chronic inflammation as the main pathological cause of diabetic nephropathy (DN). Exploration of key targets in the inflammatory pathway may provide ...
Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors
Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors
A large number of inhibitory receptors recruit SHP1 and/or SHP2, tandem-SH2-containing phosphatases through phosphotyrosine-based motifs immunoreceptor tyrosine-based inhibitory mo...
Macrophage SHP2 Deficiency Alleviates Diabetic Nephropathy via Suppression of MAPK/NF-κB– Dependent Inflammation
Macrophage SHP2 Deficiency Alleviates Diabetic Nephropathy via Suppression of MAPK/NF-κB– Dependent Inflammation
Increasing evidence implicates chronic inflammation as the main pathological cause of diabetic nephropathy (DN). Exploration of key targets in the inflammatory pathway may provide ...
Abstract 360: Leveraging a novel ITIM motif in GPCRs for targeted antibody design
Abstract 360: Leveraging a novel ITIM motif in GPCRs for targeted antibody design
Abstract
CXCR4, a chemokine GPCR, is essential for migration of neuronal, hematopoietic, and breast cancer cells during metastasis whereby CXCR4 dysregulation promot...
Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity
Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity
Src homology 2 domain-containing phosphatase 2 (SHP2) is an attractive target for cancer therapy due to its multifaceted roles in both tumor and immune cells. Herein, we designed a...
Molecular Features Underlying Shp1/Shp2 Discrimination by Immune Checkpoint Receptors
Molecular Features Underlying Shp1/Shp2 Discrimination by Immune Checkpoint Receptors
Abstract
Numerous inhibitory immunoreceptors operate by recruiting phosphatase effectors Shp1 and Shp2 through conserved motifs ITIM and ITSM. Despite the similarit...
Increased Expression of Tyrosine Phosphatase SHP2 in Experimental Pneumococcal Meningitis: Correlation With Tumor Necrosis Factor-Alpha and Cerebrospinal Fluid Pleocytosis
Increased Expression of Tyrosine Phosphatase SHP2 in Experimental Pneumococcal Meningitis: Correlation With Tumor Necrosis Factor-Alpha and Cerebrospinal Fluid Pleocytosis
Protein tyrosine phosphatase SHP2 plays a crucial role in the development of the central nervous system. To explore the expression and possible role of SHP2 during the course of ba...

